Therapeutic cure rate at first follow-up was higher in the rifaximin 25mg/5 days ( 48 % , P = 0.04 ) , 100mg/2 days ( 36.0 % ) , and 100mg/5 days ( 25.9 % ) groups than in the placebo group ( 19.0 % ) .
